Guided Thera Financials
Guided Thera (GTHP) reported $767K in revenue for fiscal year 2025, up 10857.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Tiny sales sit beside a persistent cash burn, so external funding still matters more than operating scale.
After revenue rebounded from$7K in FY2024 to$767K in FY2025, the business still used cash at nearly the same rate, showing that higher sales have not yet covered the fixed cost base. That is why a strong74.5% gross margin could coexist with operating cash flow of-$1.07M : unit economics improved, but company-level economics are still dominated by overhead and financing needs.
Liquidity tightened in FY2025 because financing inflows of
Working capital is not very liquid: inventory was
Financial Health Signals
Guided Thera does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Guided Thera scores -174.89, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($24.1M) relative to total liabilities ($7.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Guided Thera passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Guided Thera reported a net loss of $3.2M while operations used $1.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Guided Thera reported an operating loss of $2.4M against $617K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Guided Thera generated $767K in revenue in fiscal year 2025. This represents an increase of 10857.1% from the prior year.
Guided Thera's EBITDA was -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 12.5% from the prior year.
Guided Thera reported -$3.2M in net income in fiscal year 2025. This represents a decrease of 32.2% from the prior year.
Cash & Balance Sheet
Guided Thera recorded an outflow of $1.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 4.4% from the prior year.
Guided Thera held $63K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Guided Thera's gross margin was 74.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 45.9 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for fiscal year 2025.
Capital Allocation
Guided Thera invested $469K in research and development in fiscal year 2025. This represents a decrease of 10.8% from the prior year.
Guided Thera invested $2K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
GTHP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | N/A | $60K-48.7% | $117K | $0 | N/A | $0 |
| Cost of Revenue | $0 | $0 | N/A | $25K-34.2% | $38K | $0 | N/A | $0 |
| Gross Profit | $0 | $0 | N/A | $35K-55.7% | $79K | $0 | N/A | $0 |
| R&D Expenses | $34K-24.4% | $45K | N/A | $136K+2.3% | $133K+79.7% | $74K | N/A | $111K |
| SG&A Expenses | $423K-6.2% | $451K | N/A | $362K-45.0% | $658K+146.4% | $267K | N/A | $374K |
| Operating Income | -$478K-58.3% | -$302K | N/A | -$485K+36.4% | -$763K-84.3% | -$414K | N/A | -$561K |
| Interest Expense | $136K-9.9% | $151K | N/A | $129K-17.8% | $157K+6.8% | $147K | N/A | $108K |
| Income Tax | $0 | $0 | N/A | $0 | $0 | $0 | N/A | $0 |
| Net Income | -$605K-21.0% | -$500K | N/A | -$742K+8.5% | -$811K-89.9% | -$427K | N/A | -$654K |
| EPS (Diluted) | -$0.010.0% | -$0.010.0% | -$0.010.0% | -$0.010.0% | -$0.01 | -$0.01+50.0% | -$0.02-100.0% | -$0.01 |
GTHP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.2M-25.5% | $1.6M+21.1% | $1.3M+46.6% | $903K-3.9% | $940K-2.8% | $967K-29.8% | $1.4M+10.3% | $1.2M |
| Current Assets | $527K-42.2% | $911K+50.6% | $605K-24.3% | $799K-1.5% | $811K0.0% | $811K-32.2% | $1.2M+14.8% | $1.0M |
| Cash & Equivalents | $12K-96.7% | $369K+485.7% | $63K-27.6% | $87K-53.0% | $185K+60.9% | $115K-70.4% | $388K+100.0% | $194K |
| Inventory | $500K+6.6% | $469K+4.7% | $448K-23.2% | $583K-2.0% | $595K-6.0% | $633K0.0% | $633K-0.5% | $636K |
| Accounts Receivable | $4K0.0% | $4K0.0% | $4K-33.3% | $6K-25.0% | $8K+300.0% | $2K-33.3% | $3K+50.0% | $2K |
| Total Liabilities | $7.0M+2.6% | $6.8M-7.5% | $7.3M+11.9% | $6.5M+2.1% | $6.4M+7.0% | $6.0M-4.3% | $6.3M+1.6% | $6.2M |
| Current Liabilities | $6.2M+3.5% | $6.0M-10.2% | $6.6M+2.6% | $6.5M+1.5% | $6.4M+8.1% | $5.9M-4.2% | $6.2M+2.2% | $6.0M |
| Long-Term Debt | $53K-41.8% | $91K | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$5.8M-11.3% | -$5.2M+13.8% | -$6.0M-6.4% | -$5.6M-3.2% | -$5.5M-8.8% | -$5.0M-2.8% | -$4.9M+0.6% | -$4.9M |
| Retained Earnings | -$158.7M-0.4% | -$158.1M-0.6% | -$157.1M-0.8% | -$155.8M-0.5% | -$155.0M-0.6% | -$154.2M-0.3% | -$153.7M-0.5% | -$153.0M |
Not reported in any period shown, so not listed: Goodwill.
GTHP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$319K+48.3% | -$617K-112.0% | -$291K-5.1% | -$277K-63.9% | -$169K+48.9% | -$331K+0.3% | -$332K+29.8% | -$473K |
| Capital Expenditures | N/A | N/A | $0 | N/A | N/A | N/A | $0 | N/A |
| Free Cash Flow | N/A | N/A | -$291K | N/A | N/A | N/A | -$332K | N/A |
| Investing Cash Flow | N/A | N/A | $0 | N/A | N/A | N/A | $0 | N/A |
| Financing Cash Flow | -$38K-104.1% | $923K+245.7% | $267K+47.5% | $181K-24.3% | $239K+312.1% | $58K-89.0% | $526K+34.2% | $392K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
GTHP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | 58.3%-9.2pp | 67.5% | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | -808.3% | -652.1% | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | -1236.7% | -693.2% | N/A | N/A | N/A |
| Return on Assets | -50.6%-19.5pp | -31.2% | N/A | -82.2%+4.1pp | -86.3%-42.1pp | -44.2% | N/A | -52.4% |
| Current Ratio | 0.09-0.1x | 0.15+0.1x | 0.090.0x | 0.120.0x | 0.130.0x | 0.14-0.1x | 0.190.0x | 0.17 |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$6.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Guided Thera Ranks
Frequently Asked Questions
What is Guided Thera's annual revenue?
Guided Thera (GTHP) reported $767K in total revenue for fiscal year 2025. This represents a 10857.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Guided Thera's revenue growing?
Guided Thera (GTHP) revenue grew by 10857.1% year-over-year, from $7K to $767K in fiscal year 2025.
Is Guided Thera profitable?
No, Guided Thera (GTHP) reported a net income of -$3.2M in fiscal year 2025.
What is Guided Thera's EBITDA?
Guided Thera (GTHP) had EBITDA of -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Guided Thera's gross margin?
Guided Thera (GTHP) had a gross margin of 74.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Guided Thera's free cash flow?
Guided Thera (GTHP) recorded an outflow of $1.1M in free cash flow during fiscal year 2025. This represents a 4.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Guided Thera's operating cash flow?
Guided Thera (GTHP) recorded an outflow of $1.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Guided Thera's total assets?
Guided Thera (GTHP) had $1.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Guided Thera's capital expenditures?
Guided Thera (GTHP) invested $2K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Guided Thera spend on research and development?
Guided Thera (GTHP) invested $469K in research and development during fiscal year 2025.
What is Guided Thera's current ratio?
Guided Thera (GTHP) had a current ratio of 0.09 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Guided Thera's return on assets (ROA)?
Guided Thera (GTHP) had a return on assets of -241.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Guided Thera's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Guided Thera (GTHP) held $63K in cash, cash equivalents and investments, and reported an operating cash outflow of $1.1M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Guided Thera's debt-to-equity ratio negative or not reported?
Guided Thera (GTHP) has negative shareholder equity of -$6.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Guided Thera's Altman Z-Score?
Guided Thera (GTHP) has an Altman Z-Score of -174.89, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Guided Thera's Piotroski F-Score?
Guided Thera (GTHP) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Guided Thera's earnings high quality?
Guided Thera (GTHP) reported a net loss of $3.2M while operations used $1.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Guided Thera cover its interest payments?
Guided Thera (GTHP) reported an operating loss of $2.4M against $617K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.